Overview

• The CHA2DS2-VASc-Biomarkers model integrates NT-proBNP and growth differentiation factor 15 levels with traditional clinical factors to measure stroke risk more accurately.
• Analysis of 713 anticoagulated patients followed for 12 years and 2,400 non-anticoagulated participants over 13 years identified key biomarkers linked to breakthrough strokes.
• The enhanced score aims to optimize anticoagulant prescribing by identifying high-risk patients who would benefit most and reducing unnecessary bleeding complications.
• Atrial fibrillation affects approximately 10.5 million Americans and is a leading cause of stroke.
• Developed at the University of Vermont with NIH/NINDS funding using data from the national REGARDS cohort, the calculator is freely available online for clinicians.